All News

ACR Clean (Keep)

ACR Update on Tocilizumab Shortages

d ACR

The American College of Rheumatology (ACR) is actively engaged with the FDA Center for Drug Evaluation and Research (CDER) drug shortage team as they work with the manufacturer to resolve current shortages of tocilizumab (Actemra).

Read Article
mask.cough_.URI_.jpg

Non-Serious Infection Risk with Biologics in RA

d Jack Cush, MD

Nonserious infections (NSI) comprise the bulk of all infections seen with biologic therapies; new data from British Society for Rheumatology Biologics Register for Rheumatoid Arthritis shows that while NSI are more common than serious infections, the predictors of NSI are the same as serious infections.

Read Article
RA Hands Difficult deformity

What Factors Predict RA in First-Degree Relatives?

d MedPage Today

Among a cohort of first-degree relatives of patients with rheumatoid arthritis (RA), certain patient characteristics, as well as symptoms, helped predict a possible increased risk for developing the disease, U.K. researchers reported.

Read Article
vaccination.jpg

Booster Shots for Rheumatology Patients on Immunosuppressive Medications

d ACR Press Release

ATLANTA – The CDC's Advisory Committee on Immunization Practices today recommended that rheumatology patients being actively treated with high-dose corticosteroids, alkylating agents, antimetabolites, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory receive a third dose of the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines.

Read Article
Important read re:G6PD testing prior to HCQ Rare & not assoc w/hemolytic anemia in this cohort, but only 11 pts with G6PDH deficiency I'm v. skeptical of G6PD screening; cost (no HCQ in SLE) could easily be worse than benefit (avoiding hemolytic anemia) Do you routinely test? https://t.co/HI2PuF1Xq9
Mike Putman EBRheum ( View Tweet)
Check for APAs and LAC in SLE pts with hemolytic anemia https://t.co/hlGfnq89Pz

Links:

k dao KDAO2011 ( View Tweet)

Oligoarticular Versus Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics https://t.co/bIPdfUIL5S via @docguide 39% oligo progress to poly - what about response to therapy - likely the same?

Links:

Peter Nash drpnash ( View Tweet)

Using data from Framingham Study, 347 pt w/ Widespread Pain (WP) compared to 2117 without. WP was associated with an increased risk of all-cause dementia (HR: 1.43), Alzheimer's (HR: 1.47) and stroke risk (HR: 1.29). https://t.co/S1CS01zNkJ

Links:

Dr. John Cush RheumNow ( View Tweet)

Sporadic reports of anakinra use in COVID-19 infection has hinted is potential; now a metanalysis shows that the use of anakinra may reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia. https://t.co/VBxg9fQmt0 https://t.co/ARX2C0WRJ1

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of 7815 RA patients (female, 85%) w/ 340 H. Zoster events (309 pts). HZ rates were lower in men vs women 8.5 vs 11 HZ/1000 Pt-Yrs. Zoser Risk factors: incr HAQ (OR 1.51), MTX use (1.58), and biologic use (1.88) https://t.co/p0MTlwgJ8g Conclusions

Links:

Dr. John Cush RheumNow ( View Tweet)

Among a cohort of first-degree relatives of patients with rheumatoid arthritis (RA), certain patient characteristics, as well as symptoms, helped predict a possible increased risk for developing the disease, U.K. researchers reported. https://t.co/7geaJDO8O8 https://t.co/opIu4gXxin

Links:

Dr. John Cush RheumNow ( View Tweet)
https://t.co/lRr1EsoADU EULAR 2021: Still’s Disease Highlights Sponsored by Novartis Medical Affairs Listen to a discussion of medical experts discuss insights from independently selected abstracts in Still’s disease.

Links:

Dr. John Cush RheumNow ( View Tweet)

16 Pts on mech ventilation for SARS-CoV-2- induced ARDS with hyperinflammation were treated with ruxolitinib plus standard care - 13/16 survived 28 days. Better outcomes seen w/ RUX and Lymph-neutrophil ration > 0.07. https://t.co/4O2Y5swE0x

Links:

Dr. John Cush RheumNow ( View Tweet)

In the week ending 8/12: 👧🏽121,427 pediatric #COVID19 cases (14.4% of all cases, 49 states) 🏥452 pediatric hospitalizations (24 states reporting) 💀7 pediatric deaths (43 states reporting) One death is too many.

Shematologist, MD acweyand ( View Tweet)

Here is a fairly obvious piece of advice: If a patient presents with a diagnosis (self-made) rather than a symptom, work hard to clarify the symptom itself. You usually make the same diagnosis but not always...

Adam Cifu adamcifu ( View Tweet)

Scottish study of 78 000 veterans shows no association between military service and future OA knee/hip. 78K Vets compared to 253K non-Vets shows Vets with a lower risk of THR (HR 0.87), but not TKR (HR 1.02). https://t.co/JU7Q80qji1

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of Colchicine in oronary artery disease (CAD) (13RCTs, n=13125), colchicine signif. reduces the risk of MI (OR 0.64) & CVA/TIA (OR 0.50), but has a higher rate of GI upset with no influence on all‐cause mortality (OR 0.96) https://t.co/CRDUFsc6lG

Links:

Dr. John Cush RheumNow ( View Tweet)

Osteoarthritis vs. Rheumatoid Arthritis https://t.co/qvVEcKqNAM https://t.co/WDyIZxoL7v

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch Now: The Sentinel Joint: Dr. Kathryn Dao ( @KDAO2011 ) reviews abstract POS0385 presented at the virtual EULAR 2021 meeting. https://t.co/H3DcSHQWHr https://t.co/f7LDNz6oyL

Links:

Dr. John Cush RheumNow ( View Tweet)
Popular on RheumNow https://t.co/BZsl8a6ArW The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/RNFsJadUZx

Links:

Dr. John Cush RheumNow ( View Tweet)
×